Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Uppsala – page 28

334 clinical trials in Uppsala, Sweden across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Uppsala at a glance
334
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

334 trials in Uppsala

Open in trial search

Neuroendocrine carcinoma metastatic

Not recruiting
InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Human Adenovirus C Serotype 5 With E1 Gene Controlled By Chromogranin A Promoter And Hexon Modified With Protein Transduction Domain Motif
  • Sponsor:Uppsala University

Plasma cell myeloma

Not recruiting
Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ixazomib
  • Sponsor:HUS-yhtymae

Coronary artery disease

Not recruiting
Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Vaestra Goetalandsregionen

Cervix carcinoma

Not recruiting
Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Acute lymphocytic leukaemia

Not recruiting
Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Crisantaspase
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Normal pressure hydrocephalus

Not recruiting
Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Acetazolamide Sodium
  • Sponsor:Region Uppsala

Type 1 diabetes mellitus

Not recruiting
Registered drug
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Ixekizumab
  • Sponsor:NU Hospital Group-Vaestra Goetalandsregionen

Bladder transitional cell carcinoma+2

Not recruiting
Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Gilead Sciences Inc.

Mantle cell lymphoma stage II+2

Not recruiting
Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Ibrutinib
  • Sponsor:Klinikum Der Universitat Munchen AöR

Nephropathy

Not recruiting
Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Povetacicept
  • Sponsor:Alpine Immune Sciences Inc.

Other cities in Sweden

The busiest research cities in the country

All 65 cities in Sweden

Clinical research in Uppsala

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic breast cancer and prostate cancer treatments, including targeted therapies and novel drug combinations.

  • Advanced breast cancer treatments
  • Prostate cancer therapies
  • Colorectal cancer studies

Particular emphasis on HER2-positive breast cancer imaging and treatment optimization.

02 Metabolic Disorders

Research initiatives targeting obesity management and metabolic health, with studies evaluating new therapeutic approaches for weight management in both adults and adolescents.

  • Weight management treatments
  • Adolescent obesity studies
  • Metabolic health interventions

Focus on innovative drug combinations and long-term effectiveness studies.

03 Cardiovascular and Renal Studies

Comprehensive research on heart failure prevention and chronic kidney disease management, investigating new therapeutic combinations.

  • Heart failure prevention
  • Kidney disease treatments
  • Hypertension management

Emphasis on combination therapies and preventive approaches.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.